The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have been established as the standard therapy for EGFR-sensitizing mutant advanced non-small-cell lung cancer (NSCLC). However, patients ultimately develop resistance to these drugs. There are several mechanisms of both primary a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Wen-Zhao, Zhou, Qing, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642641/
https://www.ncbi.nlm.nih.gov/pubmed/29050366
http://dx.doi.org/10.18632/oncotarget.20311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642641/
https://www.ncbi.nlm.nih.gov/pubmed/29050366
http://dx.doi.org/10.18632/oncotarget.20311

Ejemplares similares